Patent ID: 11951166
Assignee: BAYER AKTIENGESELLSCHAFT
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 13:
14. A pharmaceutical combination comprising chemotherapeutic agents, wherein the chemotherapeutic agents are separate from one another and consist of
a) regorafenib or its hydrate, solvate, metabolite, pharmaceutically acceptable salt, or a polymorph thereof and
b) an anti-PD-1 antibody that inhibits PD-1,
wherein the regorafenib metabolite is selected from the group consisting of:
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide I-oxide,
4-[4({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-(hydroxymethyl)pyridine-2-carboxamide,
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide and
4-[4-({[4-chloro-3(trifluoromethyl)phenyl] carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxamide I-oxide.